16–18 Dec 2022
Birla Institute of Technology, Mesra
Asia/Kolkata timezone

Registrations are open!

Drug and its Chirality: Therapeutic Correlation

Not scheduled
10m
Birla Institute of Technology, Mesra

Birla Institute of Technology, Mesra

Department of Pharmaceutical Sciences & Technology
Poster Pharmaceutical Sciences & Technology Poster Presentation

Speaker

Ms Shweta Shweta (Birla Institute of Technology, Mesra)

Description

Drug and its Chirality: Therapeutic Correlation
Shweta1, Ghosh Manik*1
1Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology,
Mesra, Ranchi, Jharkhand, 835215, INDIA
[email protected]

ABSTRACT
The potency, pharmacological activity, metabolism, plasma disposition, toxicity, and excretion kinetics of an isomer of a physiologically active molecule might vary. All kinds of therapeutically effective drugs, including chiral compounds utilized in clinical oncology, are affected by the condition. It is a usual practice to provide a racemic mixture of the isomers of chiral anticancer drugs that reside as pair of enantiomers (50:50). Only one of the enantiomers may have the necessary pharmacological action while the other is mostly or entirely to blame for the toxicity that has been seen. The toxic effects of the ineffective isomer might make the difference between an anticancer medication that is clinically helpful and one that is too toxic for human usage.
Many chiral substances are utilized in both conventional and experimental cancer treatment. Verapamil's (R)- and (S)-enantiomers are both effective at overcoming adriamycin resistance in various tumor lines(A2780, MCF7, etc). Because of the cardiotoxicity of (S)-isomer, which is included in the normal therapeutic formulation of verapamil, cannot be utilized in the clinical treatment of diseases that are resistant to it. While (R)-verapamil has no impact in this location, (S)-verapamil is an active calcium channel blocker. This means that (R)-verapamil would be a potent anticancer medication. There are shreds of evidence that supports using only one of the isomers of another drug (ifosfamide) may lessen the dose-limiting adverse effects.
In the future, these adverse effects could be minimized to a great extent if carefully studied. Various studies, (i.e., computational studies and stereospecific synthesis) when done subsequently and sequentially would be beneficial to achieve higher therapeutic activity and lesser adverse effects of such types of drugs.
Keywords : Isomer; Enantiomer; Chiral; Verapamil; Ifosfamide

Primary author

Ms Shweta Shweta (Birla Institute of Technology, Mesra)

Co-author

Dr Manik Ghosh (Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra)

Presentation materials

There are no materials yet.